EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Molecular, genetic, and pharmacological advances in type 2 diabetes (2015–2025)

Ricardo Romero iD

Biomolecular Concepts · 23.01.2026 · 17 (1)

DOI: 10.1515/bmc-2025-0059 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biomolecular Concepts, online erschienen am 07.07.2026. Verfasst von Ricardo Romero. Beteiligte Einrichtung: Departamento de Ciencias Naturales, Universidad Autónoma Metropolitana, Unidad Cuajimalpa, Avenida Vasco de Quiroga 4871, Col. Santa Fe Cuajimalpa, A…. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Hypoglycemic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Type 2 diabetes (T2D) is a multifactorial metabolic disorder driven by the interplay of insulin resistance, β-cell dysfunction, and complex genetic and epigenetic factors. Over the past decade (2015–2025), advances in molecular biology, genomics, and pharmacology have reshaped our understanding of its pathogenesis and treatment. Large-scale GWAS and functional genomics have clarified genetic risk loci and epigenetic mechanisms, while novel biomarkers, including circulating microRNAs and metabolomic signatures, offer potential for early detection and risk stratification. Therapeutically, incretin-based drugs, especially GLP-1 receptor agonists and dual agonists, as well as SGLT2 inhibitors, have transformed outcomes by targeting both glycemic control and cardiovascular–renal protection. These insights have also informed prevention strategies, emphasizing weight reduction, microbiome modulation, and precision interventions based on genetic risk. Yet major gaps remain, including functional annotation of risk loci, understanding of β-cell dedifferentiation and recovery, and equitable implementation across diverse populations. This review synthesizes molecular, genetic, and pharmacological progress from 2015 to 2025, highlights clinical translation, and identifies priorities for the next decade of research.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Hypoglycemic AgentsHumansEpigenesis, GeneticGlucagon-Like Peptide-1 Receptor Agonists

Stichwörter der Autor:innen

GLP-1 receptor agonistsSGLT2 inhibitorsepigeneticsgeneticstype 2 diabetes

Substanzen

Hypoglycemic AgentsGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Departamento de Ciencias Naturales, Universidad Autónoma Metropolitana, Unidad Cuajimalpa, Avenida Vasco de Quiroga 4871, Col. Santa Fe Cuajimalpa, Alcaldía Cuajimalpa de Morelos, C.P. 05348, Ciudad de México, Mexico.

ORCID-Profile: Ricardo Romero

Zitieren

APA

Romero, R. (2026). Molecular, genetic, and pharmacological advances in type 2 diabetes (2015–2025). Biomolecular Concepts, 17(1). https://doi.org/10.1515/bmc-2025-0059

Vancouver

Romero R. Molecular, genetic, and pharmacological advances in type 2 diabetes (2015–2025). Biomolecular Concepts. 2026;17(1). doi:10.1515/bmc-2025-0059

BibTeX
@article{Romero2026,
  author = {Romero, Ricardo},
  title = {Molecular, genetic, and pharmacological advances in type 2 diabetes (2015–2025)},
  journal = {Biomolecular Concepts},
  year = {2026},
  volume = {17},
  number = {1},
  doi = {10.1515/bmc-2025-0059}
}
Kostenlos starten →